• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Takeda

Finance

Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease (IBD)

April 5, 2018 Microbiome Times

Osaka, Japan and Somerville, MA, April 5 2017 – Finch Therapeutics, a privately held microbiome engineering company, and Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), today announced a global collaboration agreement to jointly develop FIN-524. […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
    May 25, 2023
  • DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device
    May 10, 2023
  • Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™
    April 27, 2023
  • Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
    April 25, 2023
  • Researchers create virus-resistant, safely restrained E. coli
    April 10, 2023
sign up

Sign up to the Microbiome Times newsletter